The National Health Service (NHS) in England is rolling out a treatment upgrade that will allow thousands of cancer patients to receive the immunotherapy drug pembrolizumab via a one-minute injection instead of the traditional intravenous infusion, which can take hours. This change is expected to improve patient experience and free up valuable clinical resources.
Pembrolizumab, a checkpoint inhibitor that helps the immune system recognize and attack cancer cells, has been a key treatment for various cancers including melanoma, lung cancer, and lymphoma. Previously, administration required patients to sit through an infusion lasting up to an hour or more. The new subcutaneous injection, which takes just a minute or two, offers a more convenient option. The NHS estimates that tens of thousands of patients could benefit annually from this faster delivery method.
The shift to an injection is important for several reasons. For patients, it means less time in hospital chairs, reducing disruption to their daily lives. For the healthcare system, it allows clinics to treat more patients in the same amount of time, potentially shortening waitlists. The NHS is adopting this change following positive clinical data showing that the injection is as safe and effective as the infusion.
This development also highlights the broader trend in oncology toward more patient-friendly drug formulations. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are also engaged in developing innovative cancer therapies that aim to improve delivery and efficacy. The move by the NHS could encourage other health systems to adopt similar approaches.
However, the transition requires training for healthcare staff and adjustments to supply chains. The NHS has been working with manufacturers to ensure a steady supply of the injectable form. Patient advocacy groups have welcomed the news, noting that reducing treatment burden can improve quality of life for those undergoing long-term therapy.
The implications extend beyond convenience. Faster administration may also reduce the risk of infusion-related reactions and lower the carbon footprint associated with longer clinic visits. As the NHS continues to innovate in cancer care, this change represents a practical step toward more efficient and patient-centered treatment.
For more information on the latest developments in biotechnology and life sciences, visit BioMedWire.
